Rare Driver Mutations in Advanced, Oncogene-Addicted Non-Small Cell Lung Cancer: A North Italian, Real-World, Registry Experience

Kalliopi Andrikou; Paola Ulivi; Elisabetta Petracci; Irene Azzali; Federica Bertolini; Giulia Alberti; Stefania Bettelli; Daniele Calistri; Elisa Chiadini; Laura Capelli; Paola Cravero; Giorgia Guaitoli; Francesca Zanelli; Marco Angelo Burgio; Maria E. Pagano; Alberto Verlicchi; E. Martinelli; Katia Di Emidio; Massimo Dominici; Carmine Pinto; Angelo Delmonte

doi:10.3390/diagnostics14101024

Abstract

The real-world, retrospective, NEROnE registry investigated the impact of next-generation sequencing (NGS) in advanced non-small-cell lung cancer (NSCLC) patients (pts) at three oncology units in the north of Italy between January 2020 and December 2022. We focused on the clinical characterization and outcomes of NSCLC with rare molecular alterations:

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Andrikou et al. (2024) studied this question.

synapsesocial.com/papers/68e6a135b6db6435876248df https://doi.org/10.3390/diagnostics14101024

View Full Paper

Ask AI

Bookmark

Share

Rare Driver Mutations in Advanced, Oncogene-Addicted Non-Small Cell Lung Cancer: A North Italian, Real-World, Registry Experience

Abstract

Discussion

Cite This Study

Rare Driver Mutations in Advanced, Oncogene-Addicted Non-Small Cell Lung Cancer: A North Italian, Real-World, Registry Experience

Abstract

Discussion

Cite This Study

Keep reading

Keep reading